Three days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to make many changes to deliver on...
Read MoreAlthough research has linked pre-existing intratumoral immune response—characterized by presence of tumor-infiltrating lymphocytes or cytotoxic effector T cells—with improve prognosis in early triple-negative breast cancer...
Read MoreDespite research suggesting that mutation in ESR1 is an acquired mechanism of resistance to endocrine therapy (ET), the impact of this mutation on therapy response in primary breast cancer remains unclear. To better understand...
Read MoreNew Tx available to patients who have tried two prior treatments WASHINGTON — Sacituzumab govitecan-hziy (Trodelvy) is now FDA-approved to treat adults with metastatic triple-negative breast cancer.The drug — which...
Read MoreMore than 33% of women treated with dual HER2 blockade plus docetaxel were still alive 8 years after Dx Previously reported improvements in overall survival (OS) with dual HER2 receptor blockade plus docetaxel in HER2-positive...
Read MoreBenefits and harms clarified with decision aid in women ages 75-plus Older women who received a decision aid on screening mammography before seeing their primary care physician (PCP) were less likely to choose screening,...
Read More
Patient information should be provided; well visits should be rescheduled, transitioned to telemedicine
Read MoreWith more young breast cancer survivors, a trend toward having children later in life, and improvements in assisted reproductive technology (ART), fertility preserving techniques are of growing importance prior to initiation of...
Read More
Despite treatment, elderly patients with cancer who are HIV-positive had worse outcomes than those...
Read More